Statins may reduce hepatic steatosis by activating sterol regulatory element-binding proteins (SREBPs), peroxisome proliferator-activated receptor alpha (PPARα), and β-oxidation, even if their beneficial effects in experimental steatosis remain controversial [103]. The gene discussed is PPARA; the disease is fatty liver disease.